View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Carole Braudeau
  • Carole Braudeau
AC ACCOR SA
AMS AMS AG ... (+10)

Credit Morning 09/13/2024

Elis: feedback from the ‘Credit conf call’Worldline: new profit warning, CEO resigns>...

Carole Braudeau
  • Carole Braudeau
AC ACCOR SA
AMS AMS AG ... (+10)

Morning Crédit 13/09/2024

Elis : feed-back de la visioconférence « Crédit »Worldline : nouveau profit warning et démission du CEO Gilles Grapinet>...

Christophe Chaput ... (+2)
  • Christophe Chaput
  • Hela Zarrouk

Elis : Acquisition in the US: financial discipline and synergies will ...

>Feedback from the road show with management - At a road show with Elis’ management (CEO, CFO, HIR, IR), we reviewed the group's news and mainly the possibility of acquiring Vestis. Our key takeaways: from a strategic viewpoint, Elis reiterated that the North American market represents $ 48bn (including $ 21bn for "uniforms"), i.e. 2x the size of the addressable market in Europe with average annual growth of 5-6% (vs around 3-4% in Europe). On the competition fro...

Christophe Chaput ... (+2)
  • Christophe Chaput
  • Hela Zarrouk

Elis : Acquisition aux Etats-Unis : la discipline financière et l’enve...

>Feedback roadshow management - A l’occasion d’un roadshow avec le management (CEO, CFO, HIR, IR), nous sommes revenus sur l’actualité du groupe et principalement sur la possibilité d’une acquisition de Vestis. Nous retiendrons principalement que : D’un point de vue stratégique, le groupe Elis rappelle que le marché en Amérique du nord représente 48 Md$ (dont 21 Md$ pour les « Uniforms ») soit 2x la taille du marché adressable en Europe avec une croissance annuel...

Sean Conroy
  • Sean Conroy

OSE Immunotherapeutics - Tedopi registrational study commences

OSE Immunotherapeutics has announced the initiation of its Phase III registrational study (Artemia) for lead cancer vaccine Tedopi, with the trial launching in the US, Canada, Europe and the UK. Artemia is a confirmatory pivotal trial designed to assess the efficacy and safety of Tedopi as a monotherapy versus the standard of care (SoC) in HLA-A2 positive patients with metastatic non-small cell lung cancer (NSCLC) and secondary (acquired) resistance to immune checkpoint inhibitors (ICIs). The pr...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ING Benelux Conference London Alfen Fugro Renewi Other company news D'Ieteren: €4bn dividend, family shareholder reorganization, good results Euronext: Continued Momentum Staffing: French staffing: underlying July trend weak; August outlook slightly better Events Calendar

 PRESS RELEASE

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Regi...

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer Trial begins in the United States, Canada, Europe and United Kingdom after successful regulatory authorizations in 14 countries.Trial in Progress presentation at the 2024 World Conference on Lung Cancer in San Diego and at the European Society for Medical Oncology congress 2024 in Bar...

Carole Braudeau
  • Carole Braudeau

Credit Morning 09/09/2024

Elis has confirmed that it has approached Vestis>...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 09/09/2024

Elis a confirmé avoir approché Vestis>...

Jean Danjou
  • Jean Danjou

ODDO BHF Small & MIDCAP MORNING NEWS - 09/09/2024

At the 15th edition of our Corporate Conference, hosted jointly by ODDO BHF and Commerzbank, the presenting corporates were still focused on the macroeconomic environment and the related impact on their sectors. Regionally, the US remains resilient at good levels, while China and Europe are lagging behind. Germany in particular is seen as sluggish. Hence, we observed a mixed picture across the 89 companies presenting at our conference. We were positively surprised by statements from a...

Jean Danjou
  • Jean Danjou

ODDO BHF Small & MIDCAP MORNING NEWS - 09/09/2024

At the 15th edition of our Corporate Conference, hosted jointly by ODDO BHF and Commerzbank, the presenting corporates were still focused on the macroeconomic environment and the related impact on their sectors. Regionally, the US remains resilient at good levels, while China and Europe are lagging behind. Germany in particular is seen as sluggish. Hence, we observed a mixed picture across the 89 companies presenting at our conference. We were positively surprised by statements from a...

Christophe Chaput ... (+2)
  • Christophe Chaput
  • Hela Zarrouk

Elis : Acquisition in US comes as a surprise, but Elis confirms desire...

>Elis confirmed on Friday that it had approached Vestis with a view to an acquisition - On Friday, Elis’ share price dropped by 15.66% after a Reuters article indicated that the group had approached Vestis (VSTS) regarding a potential acquisition. This rumour was confirmed by Elis’ management in a press release during the day, which said that the approach was only preliminary and that there was no guarantee discussions would lead to the signature of a transaction or a...

Christophe Chaput ... (+2)
  • Christophe Chaput
  • Hela Zarrouk

Elis : Une acquisition aux Etats-Unis constitue une surprise mais Elis...

>Elis a confirmé vendredi avoir approché Vestis en vue d’une acquisition - Vendredi, le cours d’Elis a reculé de 15.66% après un article de Reuters indiquant que le groupe avait approché Vestis (VSTS) concernant une potentielle acquisition. Cette rumeur a été confirmée par le management d’Elis dans un communiqué en cours de journée, disant que cette approche n’était que préliminaire et qu’il n’y avait aucune garantie que les discussions aboutissent à la signature d’un...

 PRESS RELEASE

Elis to host a webcast as part of non-deal roadshow

Elis to host a webcast as part of non-deal roadshow Saint-Cloud, 8 September 2024 – Elis’ management opens tomorrow, Monday 9 September, a previously scheduled non-deal investor roadshow during which the company will discuss its business and strategy. As part of this two-week roadshow, Elis will host a webcast presentation and question-and-answer session for investors and analysts on Monday September 9 at 8:00am CET with Xavier Martiré, Chairman of the Management Board and Louis Guyot, Chief Financial Officer. The link to the webcast is: The link to the conference call & Q&A session is:...

 PRESS RELEASE

Elis: Press release

Elis: Press release Saint-Cloud, 6 September 2024 – Elis confirms it has made a preliminary approach to Vestis regarding a potential acquisition. Elis regularly considers a range of strategic opportunities. There can be no assurance that these discussions will result in the signing of a transaction or other agreement. Any transaction, should one be agreed, would be in line with Elis’ commitments to its shareholders, namely: Financial discipline in terms of the amount paid for the acquisition;Retain investment grade rating and leverage of c. 2.2x adjusted EBITDA in Year 1 and c. 2.0x in...

Carole Braudeau
  • Carole Braudeau

Credit Morning 09/06/2024

Elis said to be interested by Vestis in US (Reuters) Mahle: downgraded sentiment after Q2 2024 results call Isabel Marant - conference call: New disappointment for Spring 2025 order book>...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 06/09/2024

Isabel Marant - conference call : Nouvelle déception sur le carnet de commandes du printemps 2025 Elis serait intéressé par Vestis aux Etats-Unis (Reuters) Mahle : un sentiment dégradé après le call des résultats T2 2024>...

 PRESS RELEASE

Elis: Disclosure of the number of shares forming the capital and of th...

Elis: Disclosure of the number of shares forming the capital and of the total number of voting rights as of 31 08 2024 DECLARATION DU NOMBRE D’ACTIONS COMPOSANT LE CAPITALET DU NOMBRE TOTAL DE DROITS DE VOTE AU 31 AOUT 2024 Article L. 233-8-II du Code de CommerceArticle 223-16 du Règlement général de l’AMF Nombre d’actions composant le capital social235 567 817Nombre de droits de vote théoriques267 565 661Nombre de droits de vote exerçables267 512 953 Cette déclaration est en ligne sur le site internet d’Elis DISCLOSURE OF THE NUMBER OF SHARES FORMING THE CAPITALAND OF THE TOTAL NUMBER O...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch